약물방출 스텐트 개발의 최신 동향 (Drug-Eluting Stents) (An Overview of Researches Trend in Drug-Eluting Stents Development)

서지정보

· 발행기관 : 한국생체재료학회
· 수록지 정보 : 생체재료학회지 / 14권 / 1호 / 37 ~ 49페이지
· 저자명 : 김순중, 박재근, 김정호, 권일근

초록

Since A. Gruentzig performed successful balloon dilatation of coronary artery stenosis in a patient in 1977, the devel-opment of interventional treatment of coronary artery disease was truly remarkable. The percutaneous coronary inter-vention (PCI) has been a great advance in the treatment of coronary artery disease since implantation of bare metal stents (BMS) decreased acute recoil and arterial shrinkage caused by balloon angioplasty. However, neointimal hyper-plasia leading to in-stent restenosis after BMS implantation has been emerged a new obstacle. Recent introduction of drug-eluting stents (DES) contributes a powerful breakthrough to PCI. DES overcame restenosis, the impregnable lim-itation of PCI. Many large well-controlled randomized trials have shown that DES remarkably reduces restenosis and target vessel revascularization in de novo lesions when compared with BMS. Therefore the application of DES have been expanded to the complex lesions such as left main, multi-vessel, bifurcation, in-stent restenosis, or chronic total occlusion. The safety and effectiveness of DES are still under evaluation with ongoing trials. However, some problems such as very late stent thrombosis remained to be solved. In this review article, we summarize research trend in DES development.

영어초록

Since A. Gruentzig performed successful balloon dilatation of coronary artery stenosis in a patient in 1977, the devel-opment of interventional treatment of coronary artery disease was truly remarkable. The percutaneous coronary inter-vention (PCI) has been a great advance in the treatment of coronary artery disease since implantation of bare metal stents (BMS) decreased acute recoil and arterial shrinkage caused by balloon angioplasty. However, neointimal hyper-plasia leading to in-stent restenosis after BMS implantation has been emerged a new obstacle. Recent introduction of drug-eluting stents (DES) contributes a powerful breakthrough to PCI. DES overcame restenosis, the impregnable lim-itation of PCI. Many large well-controlled randomized trials have shown that DES remarkably reduces restenosis and target vessel revascularization in de novo lesions when compared with BMS. Therefore the application of DES have been expanded to the complex lesions such as left main, multi-vessel, bifurcation, in-stent restenosis, or chronic total occlusion. The safety and effectiveness of DES are still under evaluation with ongoing trials. However, some problems such as very late stent thrombosis remained to be solved. In this review article, we summarize research trend in DES development.

참고자료

· 없음